{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T16:21:10Z","timestamp":1720542070321},"reference-count":74,"publisher":"Wiley","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1393,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1111\/j.1600-0404.2011.01603.x","type":"journal-article","created":{"date-parts":[[2011,11,8]],"date-time":"2011-11-08T02:01:25Z","timestamp":1320717685000},"page":"83-91","source":"Crossref","is-referenced-by-count":12,"special_numbering":"supplement s192","title":["Balancing clinical benefits of vigabatrin with its associated risk of vision loss"],"prefix":"10.1155","volume":"124","author":[{"given":"J. M.","family":"Pellock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,11,8]]},"reference":[{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1017\/S1092852900008464","article-title":"The consequences of uncontrolled epilepsy","volume":"9","author":"Sperling","year":"2004","journal-title":"CNS Spectr"},{"issue":"Suppl. 11","key":"10.1111\/j.1600-0404.2011.01603.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1528-1167.2005.00411.x","article-title":"Sudden unexpected death in epilepsy: a review of incidence and risk factors","volume":"46","author":"Tomson","year":"2005","journal-title":"Epilepsia"},{"issue":"Suppl. 5","key":"10.1111\/j.1600-0404.2011.01603.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.0013-9580.2004.05005.x","article-title":"Following catastrophic epilepsy patients from childhood to adulthood","volume":"45","author":"Glauser","year":"2004","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0387-7604(01)00307-2","article-title":"Long-term outcome of patients with West syndrome","volume":"23","author":"Riikonen","year":"2001","journal-title":"Brain Dev"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2165\/00002018-200124110-00003","article-title":"A risk-benefit assessment of treatments for infantile spasms","volume":"24","author":"Nabbout","year":"2001","journal-title":"Drug Saf"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa0911610","article-title":"Long-term mortality in childhood-onset epilepsy","volume":"363","author":"Sillanp\u00e4\u00e4","year":"2010","journal-title":"N Engl J Med"},{"issue":"Suppl. 192","key":"10.1111\/j.1600-0404.2011.01603.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1600-0404.2011.01596.x","article-title":"Mechanism of action of vigabatrin: correcting misperceptions","volume":"124","author":"Ben-Menachem","year":"2011","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1111\/j.1528-1157.1999.tb02049.x","article-title":"Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms","volume":"40","author":"Appleton","year":"1999","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1212\/WNL.37.2.184","article-title":"Vigabatrin for refractory complex partial seizures: multicenter single-blind study with long-term follow-up","volume":"37","author":"Browne","year":"1987","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB11|cit11","first-page":"S52","article-title":"Therapeutic trial of vigabatrin in refractory infantile spasms","volume":"2","author":"Chiron","year":"1991","journal-title":"J Child Neurol"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1528-1157.1999.tb01991.x","article-title":"Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures","volume":"40","author":"Dean","year":"1999","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1212\/WNL.57.8.1416","article-title":"Randomized trial of vigabatrin in patients with infantile spasms","volume":"57","author":"Elterman","year":"2001","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1177\/0883073810365103","article-title":"Vigabatrin for the treatment of infantile spasms: final report of a randomized trial","volume":"25","author":"Elterman","year":"2010","journal-title":"J Child Neurol"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1212\/WNL.46.1.54","article-title":"A double-blind, placebo-controlled study of vigabatrin three g\/day in patients with uncontrolled complex partial seizures. Vigabatrin protocol 024 investigative cohort","volume":"46","author":"French","year":"1996","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/ana.410170307","article-title":"\u03b3-Vinyl GABA: a double-blind placebo-controlled trial in partial epilepsy","volume":"17","author":"Gram","year":"1985","journal-title":"Ann Neurol"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/jnnp.57.9.1057","article-title":"Effects of vigabatrin on partial seizures and cognitive function","volume":"57","author":"Gr\u00fcnewald","year":"1994","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB18|cit18","first-page":"CD007302","article-title":"Vigabatrin for refractory partial epilepsy","volume":"3","author":"Hemming","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1528-1157.1986.tb03512.x","article-title":"Double-blind, placebo-controlled study of vigabatrin (gamma-vinyl GABA) in drug-resistant epilepsy","volume":"27","author":"Loiseau","year":"1986","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/j.1528-1157.1993.tb02115.x","article-title":"Adjuvant vigabatrin in refractory epilepsy: a ceiling to effective dosage in individual patients?","volume":"34","author":"McKee","year":"1993","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(84)92112-3","article-title":"Double-blind study of \u03b3-Vinyl GABA in patients with refractory epilepsy","volume":"1","author":"Rimmer","year":"1984","journal-title":"Lancet"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1528-1157.1986.tb03600.x","article-title":"Vigabatrin in the treatment of epilepsy: a double-blind, placebo-controlled study","volume":"27","author":"Tartara","year":"1986","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/archneur.1987.00520210009010","article-title":"Double-blind study of vigabatrin in the treatment of drug-resistant epilepsy","volume":"44","author":"Tassinari","year":"1987","journal-title":"Arch Neurol"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1528-1167.2008.01988.x","article-title":"Vigabatrin: 2008 update","volume":"50","author":"Willmore","year":"2009","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1111\/j.1528-1157.1997.tb00063.x","article-title":"Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study","volume":"38","author":"Vigevano","year":"1997","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/j.1528-1157.1999.tb00802.x","article-title":"Treatment of infantile spasms: results of a population-based study with vigabatrin as the first drug for spasms","volume":"40","author":"Granstr\u00f6m","year":"1999","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S1474-4422(05)70199-X","article-title":"The United Kingdom infantile spasms study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14\u2003months: a multicentre randomised trial","volume":"4","author":"Lux","year":"2005","journal-title":"Lancet Neurol"},{"issue":"Suppl. 192","key":"10.1111\/j.1600-0404.2011.01603.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1600-0404.2011.01598.x","article-title":"Vigabatrin therapy for refractory complex partial seizures: review of major US trials","volume":"124","author":"Faught","year":"2011","journal-title":"Acta Neurol Scand"},{"issue":"Suppl. 192","key":"10.1111\/j.1600-0404.2011.01603.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1600-0404.2011.01597.x","article-title":"Vigabatrin therapy for refractory complex partial seizures: review of major European trials","volume":"124","author":"Ben-Menachem","year":"2011","journal-title":"Acta Neurol Scand"},{"issue":"Suppl. 192","key":"10.1111\/j.1600-0404.2011.01603.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1600-0404.2011.01599.x","article-title":"Vigabatrin therapy for infantile spasms: review of major trials in Europe, Canada, and the United States; and recommendations for dosing","volume":"124","author":"Carmant","year":"2011","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3109\/01658100903582498","article-title":"Evidence-based review of recommendations for visual function testing in patients treated with vigabatrin","volume":"34","author":"Sergott","year":"2010","journal-title":"Neuroophthalmology"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/j.1528-1167.2007.01133.x","article-title":"Vigabatrin and epilepsy: lessons learned","volume":"48","author":"Wild","year":"2007","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2165\/00023210-200115030-00005","article-title":"Visual field defects with vigabatrin: epidemiology and therapeutic implications","volume":"15","author":"K\u00e4lvi\u00e4inen","year":"2001","journal-title":"CNS Drugs"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.eplepsyres.2006.03.012","article-title":"A pharmacogenetic exploration of vigabatrin-induced visual field constriction","volume":"70","author":"Kinirons","year":"2006","journal-title":"Epilepsy Res"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2165\/11317650-000000000-00000","article-title":"Visual field loss in patients with refractory partial epilepsy treated with vigabatrin: final results from an open-label, observational, multicentre study","volume":"23","author":"Wild","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1111\/j.1528-1167.2010.02772.x","article-title":"Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review","volume":"51","author":"Maguire","year":"2010","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1212\/WNL.53.5.922","article-title":"Vigabatrin, a GABAergic antiepileptic drug, causes concentric visual field defects","volume":"53","author":"K\u00e4lvi\u00e4inen","year":"1999","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1046\/j.1528-1157.2001.28600.x","article-title":"Vigabatrin visual toxicity: evolution and dose dependence","volume":"42","author":"Malmgren","year":"2001","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/bjo.84.5.499","article-title":"A controlled study of vigabatrin and visual abnormalities","volume":"84","author":"Manuchehri","year":"2000","journal-title":"Br J Ophthalmol"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1046\/j.1528-1157.2002.42001.x","article-title":"The effect on vision of associated treatments in patients taking vigabatrin: carbamazepine versus valproate","volume":"43","author":"Arndt","year":"2002","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1528-1167.2007.01249.x","article-title":"Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy","volume":"49","author":"Conway","year":"2008","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB42|cit42","unstructured":"Pellock JM Benefit\/risk considerations for Sabril \u00ae (vigabatrin) 2010"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1528-1167.2008.01961.x","article-title":"Visual fields at school-age in children treated with vigabatrin in infancy","volume":"50","author":"Gaily","year":"2009","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1177\/0883073810390213","article-title":"Electroretinogram changes in a pediatric population with epilepsy: is vigabatrin acting alone?","volume":"26","author":"McCoy","year":"2011","journal-title":"J Child Neurol"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB45|cit45","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2147\/NDT.S5236","article-title":"Treatment of refractory complex partial seizures: role of vigabatrin","volume":"5","author":"Waterhouse","year":"2009","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB46|cit46","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.nurt.2006.11.008","article-title":"Vigabatrin","volume":"4","author":"Wheless","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB47|cit47","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1212\/WNL.53.9.2082","article-title":"Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings","volume":"53","author":"Miller","year":"1999","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1046\/j.1528-1157.2001.49299.x","article-title":"Visual function is stable in patients who continue long-term vigabatrin therapy: implications for clinical decision making","volume":"42","author":"Paul","year":"2001","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB49|cit49","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/sj.eye.6701405","article-title":"The natural history of vigabatrin associated visual field defects in patients electing to continue their medication","volume":"19","author":"Best","year":"2004","journal-title":"Eye"},{"issue":"Suppl. 192","key":"10.1111\/j.1600-0404.2011.01603.x-BIB50|cit50","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1600-0404.2011.01601.x","article-title":"Understanding and interpreting vision safety issues with vigabatrin","volume":"124","author":"Plant","year":"2011","journal-title":"Acta Neurol Scand"},{"issue":"Suppl. 192","key":"10.1111\/j.1600-0404.2011.01603.x-BIB51|cit51","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1600-0404.2011.01600.x","article-title":"Primer on visual field testing, electroretinography, and other visual assessments for patients treated with vigabatrin","volume":"124","author":"Sergott","year":"2011","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/019262338701500203","article-title":"A study of the effects of vigabatrin on the central nervous system and retina of Sprague Dawley and Lister-Hooded rats","volume":"15","author":"Butler","year":"1987","journal-title":"Toxicol Pathol"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB53|cit53","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/019262339001800201","article-title":"Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor","volume":"18","author":"Gibson","year":"1990","journal-title":"Toxicol Pathol"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB54|cit54","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1528-1157.2000.tb00134.x","article-title":"The potential for vigabatrin-induced intramyelinic edema in humans","volume":"41","author":"Cohen","year":"2000","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB55|cit55","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1528-1167.2008.01728.x","article-title":"Cerebral MRI abnormalities associated with vigabatrin therapy","volume":"50","author":"Pearl","year":"2009","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB56|cit56","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1528-1167.2008.01896.x","article-title":"Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy","volume":"50","author":"Wheless","year":"2009","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB57|cit57","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/0883073808324219","article-title":"Transient brain magnetic resonance imaging hyperintensity in basal ganglia and brain stem of epileptic infants treated with vigabatrin","volume":"24","author":"Milh","year":"2009","journal-title":"J Child Neurol"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB58|cit58","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1111\/j.1528-1167.2010.02564.x","article-title":"Vigabatrin-associated reversible MRI signal changes in patients with infantile spasms","volume":"51","author":"Dracopoulos","year":"2010","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB59|cit59","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1177\/0883073809348796","article-title":"Pathologic evidence of vacuolar myelinopathy in a child following vigabatrin administration","volume":"24","author":"Horton","year":"2009","journal-title":"J Child Neurol"},{"issue":"Suppl. 192","key":"10.1111\/j.1600-0404.2011.01603.x-BIB60|cit60","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1600-0404.2011.01602.x","article-title":"Non-vision adverse events with vigabatrin therapy","volume":"124","author":"Walker","year":"2011","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB61|cit61","volume-title":"(Vigabatrin) tablets (prescribing information)","author":"SABRIL\u00ae","year":"2010"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB62|cit62","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1136\/jnnp.56.12.1271","article-title":"Effect of vigabatrin on sedation and cognitive function in patients with refractory epilepsy","volume":"56","author":"Gillham","year":"1993","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB63|cit63","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1528-1157.1992.tb02295.x","article-title":"Effects of vigabatrin on cognitive function and mood when used as add-on therapy in patients with intractable epilepsy","volume":"33","author":"McGuire","year":"1992","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB64|cit64","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1600-0404.1996.tb00032.x","article-title":"Influence of vigabatrin on cognitive performances and behavior in patients with drug-resistant epilepsy","volume":"94","author":"Provinciali","year":"1996","journal-title":"Acta Neurol Scand"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB65|cit65","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1212\/WNL.53.7.1503","article-title":"Psychiatric adverse events during vigabatrin therapy","volume":"53","author":"Levinson","year":"1999","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB66|cit66","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/2042098611411127","article-title":"New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety?","volume":"2","author":"French","year":"2011","journal-title":"Ther Adv Drug Saf"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB67|cit67","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0387-7604(99)00113-8","article-title":"When antiepileptic drugs aggravate epilepsy","volume":"22","author":"Genton","year":"2000","journal-title":"Brain Dev"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB68|cit68","doi-asserted-by":"crossref","first-page":"880","DOI":"10.2165\/00003495-199141060-00007","article-title":"Vigabatrin","volume":"41","author":"Grant","year":"1991","journal-title":"Drugs"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB69|cit69","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1055\/s-2007-1017901","article-title":"Gabapentin","volume":"22","author":"Kramer","year":"1995","journal-title":"Aktuel Neurol"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB70|cit70","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1600-0404.1996.tb00047.x","article-title":"Seizure-inducing effects of antiepileptic drugs: a review","volume":"94","author":"Bauer","year":"1996","journal-title":"Acta Neurol Scand"},{"issue":"Suppl. 5","key":"10.1111\/j.1600-0404.2011.01603.x-BIB71|cit71","first-page":"S24","article-title":"The potential for increasing seizure frequency, relapse, and appearance of new seizure types with vigabatrin","volume":"43","author":"Lortie","year":"1993","journal-title":"Neurology"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB72|cit72","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1111\/j.1528-1167.2010.02657.x","article-title":"Infantile spasms: a U.S. consensus report","volume":"51","author":"Pellock","year":"2010","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB73|cit73","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1528-1167.2007.01084_2.x","article-title":"Severe relapse of epilepsy after vigabatrin withdrawal: for how long should we treat symptomatic infantile spasms?","volume":"48","author":"Kroll-Seger","year":"2007","journal-title":"Epilepsia"},{"key":"10.1111\/j.1600-0404.2011.01603.x-BIB74|cit74","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2011.08.034","article-title":"Registry initiated to characterize vision loss associated with vigabatrin therapy","author":"Pellock","year":"2011","journal-title":"Epilepsy Behav"}],"container-title":["Acta Neurologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0404.2011.01603.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1600-0404.2011.01603.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T07:49:44Z","timestamp":1671522584000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0404.2011.01603.x"}},"subtitle":["Benefit-risk considerations for vigabatrin therapy"],"short-title":[],"issued":{"date-parts":[[2011,11,8]]},"references-count":74,"URL":"https:\/\/doi.org\/10.1111\/j.1600-0404.2011.01603.x","relation":{},"ISSN":["0001-6314"],"issn-type":[{"value":"0001-6314","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11,8]]}}}